DOVBLERON 达伯乐 (Taletrectinib) 0.2g Capsules | ROS1 Inhibitor | GLT

Generic Information: DOVBLERON 达伯乐 (Taletrectinib) — Innovent China Version

DOVBLERON, sold in China under the Chinese brand name 达伯乐, is the China-marketed brand of taletrectinib (己二酸他雷替尼胶囊), marketed by Innovent Biologics (Suzhou) Co., Ltd. This page covers the 0.2 g (200 mg) capsule supplied in a 33-capsule bottle. It is important to understand the dual-brand structure of this drug: taletrectinib is a single molecule developed by AnHeart Therapeutics (now part of Nuvation Bio) and originally discovered by Daiichi Sankyo, but it is sold under two different brand names in different regions — Ibtrozi in the United States and Japan, and 达伯乐 (DOVBLERON) in China. In other words, 达伯乐 is the same drug as Ibtrozi, differing only in brand name and the company responsible for commercialization in the Chinese market.

What Is DOVBLERON 达伯乐 (Taletrectinib) Used For?

达伯乐 (DOVBLERON) is indicated in China for the treatment of ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults. It received marketing approval from the NMPA in December 2024, initially for patients whose disease has progressed after prior ROS1-TKI treatment, and it was subsequently approved for treatment-naive patients as well. ROS1-positive NSCLC is a rare but clinically significant subtype — accounting for a small percentage of lung cancer cases — that is often found in younger, never-smoking patients and has historically lacked effective targeted options. 达伯乐 fills that gap with a next-generation inhibitor that addresses both initial treatment and acquired resistance.

How Does DOVBLERON 达伯乐 (Taletrectinib) Work?

达伯乐 contains taletrectinib, a highly selective inhibitor of the ROS1 and NTRK kinases. In ROS1-positive NSCLC, a gene fusion produces an abnormal, constitutively active ROS1 protein that continuously drives tumor cell growth. Taletrectinib binds this kinase and blocks its activity, halting the oncogenic signal. What distinguishes it from earlier ROS1 inhibitors is its engineered profile: it penetrates the blood-brain barrier to reach brain metastases, and it remains active against resistant mutations — most notably G2032R, a frequent driver of resistance to first-generation inhibitors like crizotinib. This combination of brain penetration and anti-resistance activity underpins its durable clinical benefit.

Indications

达伯乐 (DOVBLERON, taletrectinib) is indicated for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer. In China it is approved for both patients who have progressed after prior ROS1-TKI therapy and treatment-naive patients, with confirmatory genetic testing for ROS1 fusion required before treatment.

Dosage

The recommended dose is 600 mg orally once daily, taken on an empty stomach (no food for at least 2 hours before and 2 hours after dosing). Each capsule contains 200 mg, so the daily dose is three capsules taken together. The 33-capsule bottle provides an 11-day supply at the standard dose. Treatment continues until disease progression or unacceptable toxicity, with dose adjustment guided by the prescribing information for adverse events such as liver enzyme elevation or QT prolongation.

Side Effects

The most common adverse reactions include elevated transaminases (AST and ALT), nausea, vomiting, anemia, diarrhea, and QT interval prolongation. Serious risks include hepatotoxicity, interstitial lung disease or pneumonitis, hyperuricemia, and myalgia with creatine phosphokinase elevation. Liver function tests should be monitored regularly, especially early in treatment, and patients should promptly report symptoms such as jaundice, new or worsening cough, or breathing difficulty.

Storage

Store 达伯乐 capsules sealed at no more than 30°C, protected from moisture. Keep out of the reach of children and do not use beyond the expiry date.

Why Choose the GLT?

达伯乐 (DOVBLERON) is the China-registered form of taletrectinib and has been included in China's national medical insurance drug list as a reimbursable category-B product, which substantially reduces out-of-pocket cost for eligible patients compared with the original launch price. For patients and institutions seeking access to this next-generation ROS1 inhibitor, GLT — a Hong Kong-licensed supplier — offers a verified channel for the authentic Innovent-marketed product, alongside the U.S.-marketed Ibtrozi, giving buyers the flexibility to choose the most appropriate and cost-effective version of the same molecule.

How to Order DOVBLERON 达伯乐 (Taletrectinib)

To order 达伯乐 (DOVBLERON), contact our team on WhatsApp at +86 15234153837 or by email at [email protected]. Please share the required quantity (0.2 g × 33 capsules), your destination country, and any documentation needs so we can confirm current availability and delivery terms.

FAQ

Is 达伯乐 (DOVBLERON) the same drug as Ibtrozi? Yes. They are the exact same molecule — taletrectinib — sold under two different brand names. Ibtrozi is the U.S./Japan brand by Nuvation Bio, while 达伯乐 (DOVBLERON) is the China brand by Innovent Biologics.

Who makes 达伯乐 (DOVBLERON)? It is marketed in China by Innovent Biologics (Suzhou) Co., Ltd., under license from Nuvation Bio, which owns the global rights to taletrectinib.

Is 达伯乐 covered by insurance in China? Yes. Taletrectinib has been included in China's national medical insurance drug list as a reimbursable category-B product, significantly lowering patient cost.

What strength is 达伯乐 available in? It is supplied as 0.2 g (200 mg) capsules, 33 capsules per bottle, with a standard dose of 600 mg (three capsules) once daily.